NEW YORK, NY--(Marketwired - Jan 9, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"), a leader in developing personalized immunocellular therapies for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback